8月3日，TG Therapeutics盘前下跌5.37%，报49.24美元/股，成交额76.17万美元。
消息面上，公司公布第二季度财报，每股收益仅为0.05美元，远低于市场一致预期的0.31-0.33美元，偏离幅度高达约85%，同比亦较去年同期的0.17美元下降逾70%。不过营收方面，公司录得2.40亿美元，超出市场预期的2.30亿美元。值得注意的是，这已是公司连续第三个季度每股收益大幅不及预期，市场对其盈利能力的担忧加剧。此前B. Riley曾将目标价上调至86美元并维持买入评级，但美银则维持"跑输大盘"评级，机构分歧明显。
TG Therapeutics是一家商业化阶段的生物制药公司，专注于B细胞介导疾病新疗法的开发，其核心产品BRIUMVI已获美国、欧盟及英国批准用于治疗复发性多发性硬化症。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.